Therapeutic Antioxidant Supplementation
Launched by SUPERFICIAL SIDEROSIS RESEARCH ALLIANCE INC. · May 12, 2021
Trial Information
Current as of November 14, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is investigating whether two oral supplements, inosine and inositol hexaphosphate, can help slow down or combat the brain and nerve damage caused by a condition called superficial siderosis. This study will look at how these supplements affect important areas such as hearing, balance, mobility, and memory over a period of three years. Participants will be monitored through surveys about their health and any changes they notice.
To be eligible for this trial, participants should have a confirmed diagnosis of superficial siderosis and experience at least one related symptom like hearing loss or balance issues. They should also be able to safely swallow large capsules and meet other health criteria. The trial is not yet recruiting, but it aims to include individuals aged 18 to 75, regardless of gender, who are not currently pregnant or breastfeeding and have not participated in another treatment study in the past month. This study will be conducted remotely, meaning participants can participate from home with regular check-ins.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Confirmed diagnosis of iSS (superficial siderosis of the CNS)
- • No illegal drug use
- • No history of myocardial infarction or stroke
- • No history of severe chronic obstructive pulmonary disease
- • Can safely swallow large capsules
- • Exhibits at least one confirmed iSS related symptom: Hearing Loss, Balance, Memory/Cognitive problems
- • Does not have a known hypersensitivity or intolerance to any study antioxidant
- • Has not taken part in another treatment study for any condition within the last 30 days (about four and a half weeks)
- • Not currently pregnant or breastfeeding
- Exclusion Criteria:
- Inosine Arm Exclusion :
- • Diagnosed with urate urolithiasis, or recurrent urolithiasis, all unknown type
- • History of Gout
- • History of Kidney Stones
- • P6 Arm Exclusion
- • Long-term anticoagulant
- • Known or suspected active bleed into the CNS
- • Currently undergoing deferiprone chelation therapy
- • Plan to begin deferiprone chelation therapy within three years
- • -
About Superficial Siderosis Research Alliance Inc.
The Superficial Siderosis Research Alliance Inc. is a dedicated organization focused on advancing research and clinical understanding of superficial siderosis, a rare neurological condition caused by the accumulation of hemosiderin in the central nervous system. Committed to fostering collaboration among researchers, healthcare professionals, and patients, the Alliance aims to accelerate the discovery of effective treatments and improve patient outcomes. Through funding innovative research initiatives and promoting awareness, the organization plays a pivotal role in enhancing the knowledge base surrounding superficial siderosis and advocating for those affected by this challenging condition.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Trial Officials
Rori-Suzanne Daniel
Study Director
Superfical Siderosis Research Alliance
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials